Web10 giu 2014 · PROTOCOL DIGEST OF JCOG1306 Objectives. The aim of this study is to confirm the non-inferiority of perioperative chemotherapy with GD to AI in patients with … Web1 lug 2024 · While ISG-STS1001 and JCOG1306 trials did not directly compare. perioperative chemotherapy and surgery, the results may suggest. that perioperative chemotherapy using a full-dose AI regimen.

A randomized Phase III trial of adjuvant S-1 therapy vs ... - PubMed

Web1 ott 2024 · We are now conducting a randomized phase II/III study, JCOG1306, to confirm the non-inferiority of neoadjuvant gemcitabine plus docetaxel (GD) to AI for high-risk … Web8 dic 2016 · Since GD can be administered in an outpatient setting due to its lower toxicities, GD is promising for further investigation by phase III trials JCOG1306 for the patients with BSTS. Conclusions This is the first report demonstrating the precise profiles of the adverse events of GD for the Japanese patients with BSTS, and one of the largest series … liberty submersible effluent pump

Colorado Title 13. Courts and Court Procedure § 13-21-1206

Web1 ott 2024 · We are now conducting a randomized phase II/III study, JCOG1306, to confirm the non-inferiority of neoadjuvant gemcitabine plus docetaxel (GD) to AI for high-risk STS. For advanced STS, adriamycin-based chemotherapy remains standard first-line treatment since phase III study of olaratumab resulted in negative. WebResults of a randomized phase II/III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus docetaxel for high-grade soft tissue sarcomas: Japan Clinical Oncology Group study JCOG1306. WebIn the phase II/III JCOG1306 trial of perioperative gemcitabine + docetaxel v adriamycin + ifosfamide in 143 pts high-risk STS, 3-yr OS was 79.2% v 91.4% (HR 2.5; P = 0.78), exceeding the prespecified non-inferiority margin. 3-year PFS was 59.1% v 79.1%: mchenry il what county